Enrollment complete in ORACLE MS study of cladribine tablets
Enrollment complete in ORACLE MS study of cladribine tablets
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the completion of patient enrollment in the ORACLE MS1 clinical study. This randomized, double blind, placebo-controlled, international Phase III trial is designed to evaluate the therapeutic effects of Cladribine Tablets on the time to conversion to multiple sclerosis (MS) in people with a first clinical event suggestive of the disease.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post